2.Research advances in add-on treatment for negative symptoms and cognitive dysfunction in schizophrenia.
Ranran LI ; Gangrui HEI ; Ye YANG ; Renrong WU ; Jingping ZHAO
Journal of Central South University(Medical Sciences) 2020;45(12):1457-1463
Antipsychotic medication is the primary treatment for schizophrenia, which is effective on ameliorating positive symptoms and can reduce the risk of recurrence, but it has limited efficacy for negative symptoms and cognitive dysfunction. The negative symptoms and cognitive dysfunction seriously affects the life quality and social function for the patients with schizophrenia. Currently, there is plenty evidence that antipsychotic drugs combined with adjuvant therapy drugs can effectively improve the negative symptoms and cognitive dysfunction. These drugs include anti-oxidants, nicotinic acetylcholine receptors and neuro-inflammatory drugs (anti-inflammatory drugs, minocycline), which show potential clinical effects.
Anti-Inflammatory Agents/therapeutic use*
;
Antipsychotic Agents/therapeutic use*
;
Cognitive Dysfunction/etiology*
;
Humans
;
Minocycline/therapeutic use*
;
Schizophrenia/drug therapy*
3.Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect.
Journal of Southern Medical University 2013;33(12):1833-1838
Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy". For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.
Anti-Inflammatory Agents, Non-Steroidal
;
therapeutic use
;
Antibodies, Monoclonal
;
therapeutic use
;
Gastrointestinal Agents
;
therapeutic use
;
Humans
;
Inflammatory Bowel Diseases
;
drug therapy
;
Infliximab
4.Research advances of Tasmayi.
China Journal of Chinese Materia Medica 2013;38(3):443-448
Tasmayi (mumie, shilajit) is a pale brown to black substance which leaks from the layers of rocks in many mountain ranges during the warm summer months. In traditional Kazakh medicine, it is used for the treatment of bone fracture and many inflammatory ailments. It is also used as a remedy in the traditional medical systems of many countries such as India, Russia and Kazakhstan. According to the literatures, Tasmayi possesses anti-inflammatory, antiulcerogenic, antibacterial, free radical scavenging, antioxidative, memory enhancing, antidiabetic, antistress, antiallergic, immunomodulative, anti AIDS, anabolic and regeneration stimulating activities. The major physiological action of Tasmayi could be belonging to the presence of dibenzo-alpha-pyrones along with humic and fulvic acids.
Animals
;
Anti-Bacterial Agents
;
therapeutic use
;
Anti-Inflammatory Agents
;
therapeutic use
;
Biomedical Research
;
methods
;
trends
;
Free Radical Scavengers
;
therapeutic use
;
Humans
;
Hypoglycemic Agents
;
therapeutic use
;
India
;
Kazakhstan
;
Medicine, Traditional
;
methods
;
trends
;
Minerals
;
therapeutic use
;
Resins, Plant
;
therapeutic use
;
Russia
6.Herbal medicine in the treatment of patients with type 2 diabetes mellitus.
Guo-Ming PANG ; Fang-Xu LI ; Yong YAN ; Yin ZHANG ; Li-Li KONG ; Pu ZHU ; Kai-Feng WANG ; Fang ZHANG ; Bin LIU ; Cheng LU
Chinese Medical Journal 2019;132(1):78-85
7.Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.
Wen-Long WEI ; Shi-Fei WU ; Hao-Jv LI ; Zhen-Wei LI ; Hua QU ; Chang-Liang YAO ; Jian-Qing ZHANG ; Jia-Yuan LI ; Wan-Ying WU ; De-An GUO
Chinese Journal of Natural Medicines (English Ed.) 2021;19(6):473-480
Huashi Baidu prescription (HSBDF), recommended in the Guideline for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Pneumonia (On Trials, the Seventh Edition), was clinically used to treat severe corona virus disease 2019 (COVID-19) with cough, blood-stained sputum, inhibited defecation, red tongue etc. symptoms. This study was aimed to elucidate and profile the knowledge on its chemical constituents and the potential anti-inflammatory effect in vitro. In the study, the chemical constituents in extract of HSBDF were characterized by UPLC-Q-TOF/MS in both negative and positive modes, and the pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assays (ELISA) to determine the effects of HSBDF in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. The results showed that a total of 217 chemical constituents were tentativedly characterized in HSBDF. Moreover, HSBDF could alleviate the expression levels of IL-6 and TNF-α in the cell models, indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 cells. We hope that the results could be served as the basic data for further study of HSBDF on anti-COVID-19 effect.
Anti-Inflammatory Agents/therapeutic use*
;
Antiviral Agents/therapeutic use*
;
COVID-19/drug therapy*
;
Drugs, Chinese Herbal/therapeutic use*
;
Humans
;
Plant Extracts/therapeutic use*
;
SARS-CoV-2/drug effects*
8.Systemic evaluation and Meta-analysis of efficacy and safety of Kangfu Xiaoyan Suppository in treatment of pelvic inflammatory disease.
Pan-Pan LI ; Yan-Ming XIE ; Wei SHI ; Lian-Xin WANG
China Journal of Chinese Materia Medica 2019;44(22):4962-4974
To evaluate the efficacy and safety of Kangfu Xiaoyan Suppository in the treatment of pelvic inflammatory disease. Four Chinese databases,namely CNKI,VIP,WanFang and SinoMed,and three English databases Cochrane Library,namely Medline,and ClinicalTrail.gov were systematically and comprehensively retrieved from the establishment of each database to June 2018. The quality of the included studies was evaluated by using the risk assessment tools developed by the Cochrane Collaboration,and RevMan 5. 3 software was used for Meta-analysis. A total of 675 articles were retrieved,and finally 56 studies were included. The total sample size was 6 228,the test group included 3 267 cases,and the control group included 2 961 cases. The overall quality of the included studies was generally low. According to the intervention measures and outcome indicators,the included studies were divided into different subgroups for analysis. The main results of Meta-analysis showed that the recurrence rate of Kangfu Xiaoyan Suppository combined with antibiotics was lower than that of antibiotics alone. Kangfu Xiaoyan Suppository combined with antibiotics was superior to antibiotics alone in terms of abdominal pain,leucorrhea abnormality relief time,mass absorption time and pain relief time. In terms of safety,Kangfu Xiaoyan Suppository combined with antibiotics had a lower incidence of adverse reactions than antibiotics alone. Based on the results of this study,it is indicated that Kangfu Xiaoyan Suppository had a certain effect on the treatment of pelvic inflammatory disease,especially with a lower recurrence rate. The long-term effect is remarkable. No serious adverse reaction was observed. Restricted by the quality of the studies included,the above conclusion need to be further verified in high-quality,largesize,multi-center clinical researches.
Anti-Bacterial Agents
;
Drugs, Chinese Herbal/therapeutic use*
;
Female
;
Humans
;
Pelvic Inflammatory Disease/drug therapy*
;
Suppositories
9.Current studies of cytokines in the pathogenesis of atherosclerosis and its therapeutic measures.
Acta Physiologica Sinica 2021;73(3):501-508
Atherosclerosis is a chronic inflammatory disease. Cytokine-related research provides an important direction for the prevention and treatment of atherosclerosis. Cytokines, produced by different types of cells and acting on a range of targets, play a key role in the pathogenesis and progression of atherosclerosis. This review summarizes the main pro-inflammatory and anti-inflammatory cytokines related to atherosclerosis and their underlying mechanism. We also outline current anti-atherosclerosis treatments targeting cytokines. The research and treatment prospects of cytokines in the prevention and treatment of atherosclerosis are discussed briefly as well.
Anti-Inflammatory Agents/therapeutic use*
;
Atherosclerosis/drug therapy*
;
Cytokines
;
Humans
;
Inflammation/drug therapy*